GTHX - G1 Therapeutics, Inc.

QQQ $ 480.40 $ -0.90 (-0.19 %)

DIA $ 409.09 $ 2.37 (0.58 %)

SPY $ 559.11 $ 5.30 (0.96 %)

TLT $ 98.30 $ 0.00 (0 %)

GLD $ 231.62 $ -0.38 (-0.16 %)

Previous Close

$ 7.09

Open

Bid

$ 7.09 x 949

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 1.08 - $ 7.12

Volume

2,853,188

Average Volume

Market Cap

372.05M

Beta (5Y Monthly)

$ 1.56

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-01-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-01-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-03-2023	03-31-2023	10-Q
7	03-01-2023	12-31-2022	10-K
8	11-02-2022	09-30-2022	10-Q
9	08-03-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	02-23-2022	12-31-2021	10-K
12	11-03-2021	09-30-2021	10-Q
13	08-04-2021	06-30-2021	10-Q
14	05-05-2021	03-31-2021	10-Q
15	02-24-2021	12-31-2020	10-K
16	11-04-2020	09-30-2020	10-Q
17	08-05-2020	06-30-2020	10-Q
18	05-06-2020	03-31-2020	10-Q
19	02-26-2020	12-31-2019	10-K
20	11-05-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	02-28-2019	12-31-2018	10-K
24	11-07-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	02-21-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

G1 Therapeutics Reaffirms FY24 COSELA Reve...
08/08/2024 10:35:14

2024 Financial Guidance G1 today reaffirmed its full year 2024 revenue guidance. G1's guidance is based on current expecta...

G1 Therapeutics Q2 2024 GAAP EPS $(0.10) B...
08/08/2024 10:33:34

G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.1...

Needham Downgrades G1 Therapeutics to Hold
08/07/2024 20:09:38

Needham analyst Gil Blum downgrades G1 Therapeutics (NASDAQ:GTHX) from Buy to Hold.

dow-tumbles-over-200-points-cvs-health-cuts-profit-forecast

Dow Tumbles Over 200 Points; CVS Health Cu...
08/07/2024 18:38:50

crude-oil-jumps-over-3-upstart-shares-spike-higher

Crude Oil Jumps Over 3%; Upstart Shares Sp...
08/07/2024 16:03:23

nasdaq-jumps-250-points-disney-earnings-beat-estimates

Nasdaq Jumps 250 Points; Disney Earnings B...
08/07/2024 14:38:26

Pharmacosmos Group To Acquire G1 Therapeut...
08/07/2024 10:35:10

G1 Therapeutics Added To Russell 2000 And ...
07/01/2024 12:11:50

HC Wainwright & Co. Maintains Buy on G1 Th...
06/25/2024 11:28:11

HC Wainwright & Co. analyst Edward White maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target ...

ball-to-rally-more-than-23-here-are-10-top-analyst-forecasts-for-tuesday

Ball To Rally More Than 23%? Here Are 10 T...
06/25/2024 11:27:06

Needham Maintains Buy on G1 Therapeutics, ...
06/25/2024 10:10:41

Needham analyst Gil Blum maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target from $12 to $6.

alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-surge

Alnylam's Closely Watched Phase 3 Heart Di...
06/24/2024 13:49:11

Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardio...

why-is-cancer-focused-g1-therapeutics-stock-trading-lower-on-monday

Why Is Cancer-Focused G1 Therapeutics Stoc...
06/24/2024 13:40:08

Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC.

G1 Therapeutics' PRESERVE 2 Phase 3 Trial ...
06/24/2024 10:34:36

The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market. G1 is Sufficiently...

Analyst Ratings For G1 Therapeutics
06/13/2024 12:00:56

Needham Reiterates Buy on G1 Therapeutics,...
06/13/2024 09:31:08

Needham analyst Gil Blum reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $12 price target.

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
06/11/2024 17:35:23

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

HC Wainwright & Co. Reiterates Buy on G1 T...
05/28/2024 16:32:53

HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics (NASDAQ:GTHX) with a Buy and maintains $9 price target.

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
05/28/2024 16:31:12